sur Immunic AG
Immunic, Inc. Set to Participate in December Investor Conference
Immunic, Inc. (Nasdaq: IMUX), a biotechnology firm focused on small molecule therapies for chronic inflammatory and autoimmune diseases, announced participation in the Piper Sandler 36th Annual Healthcare Conference. The event will be held from December 3-5, 2024, in New York. CEO Daniel Vitt, Ph.D., will engage in a fireside chat on December 5, while CFO Glenn Whaley and VP Jessica Breu will also hold one-on-one investor meetings.
The discussion and meetings aim to present the company's progress, including advancements in treatments for multiple sclerosis and ulcerative colitis. Vidofludimus calcium, their leading candidate, is undergoing phase 3 and 2 trials, showcasing neuroprotective and anti-inflammatory benefits.
Interested parties can access the event webcast on Immunic's website, with a replay available for 90 days post-conference.
R. E.
Copyright © 2024 FinanzWire, tous droits de reproduction et de représentation réservés.
Clause de non responsabilité : bien que puisées aux meilleures sources, les informations et analyses diffusées par FinanzWire sont fournies à titre indicatif et ne constituent en aucune manière une incitation à prendre position sur les marchés financiers.
Cliquez ici pour consulter le communiqué de presse ayant servi de base à la rédaction de cette brève
Voir toutes les actualités de Immunic AG